Immutep’s Phase III Halt Wipes Out Value as Adherium Jumps on RPM Revenue

• Immutep (ASX:IMM) collapsed 🔴 -88.61% after it halted its Phase III lung cancer trial on a futility call
• Adherium (ASX:ADR) jumped 🟢 25.00% on rising RPM revenue and easier US billing codes
• Imugene (ASX:IMU) fell 🔴 -21.28% even as it raised cash and reported strong early CAR-T results
• Rhythm Biosciences (ASX:RHY) gained 🟢 13.51% after NATA accreditation and its first commercial ColoSTAT® sale